Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tonkin

Showing results (11-20 of 163) with videos related to

Pageof 17
Sort By:
Bone|June 7, 2005
Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trialIan R Reid, Andrew Tonkin, Christopher P Cannon
Journal of Cardiac Failure|March 3, 2011
Nurse-led titration of β-adrenoreceptor blocking agents in chronic heart failure patients in the communityAndrea Driscoll, Henry Krum, Rory Wolfe, et al.
International Journal of Cardiology|May 8, 2018
The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspectiveRadya Kumar, Andrew Tonkin, Danny Liew, et al.
Current Opinion in Cardiology|May 29, 2014
Statins in the elderly: an answered question?Sophia Zoungas, Andrea Curtis, Andrew Tonkin, et al.
The Cochrane Database of Systematic Reviews|December 23, 2015
Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fractionAndrea Driscoll, Judy Currey, Andrew Tonkin, et al.
Heart, Lung & Circulation|December 15, 2005
What becomes of the broken hearted? Coronary heart disease as a paradigm of cardiovascular disease and poor health among indigenous australiansAlex Brown, Warren Walsh, Traven Lea, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|June 22, 2010
Best practice for prevention and treatment of cardiovascular disease through an equity lens: a reviewAlison Beauchamp, Anna Peeters, Andrew Tonkin, et al.
International Journal of Cardiology|September 18, 2018
Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspectiveZanfina Ademi, Ella Zomer, Andrew Tonkin, et al.
Clinical Pharmacology and Therapeutics|July 14, 2018
LDL-Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) RiskRichard Ofori-Asenso, Sophia Zoungas, Andrew Tonkin, et al.
Seminars in Thrombosis and Hemostasis|March 17, 2012
High platelet reactivity and antiplatelet therapy resistanceMatthew D Linden, Huyen Tran, Robyn Woods, et al.
Pageof 17

Showing results (11-20 of 163) with videos related to

Sort By:
Pageof 17
Bone|June 7, 2005
Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trialIan R Reid, Andrew Tonkin, Christopher P Cannon
Journal of Cardiac Failure|March 3, 2011
Nurse-led titration of β-adrenoreceptor blocking agents in chronic heart failure patients in the communityAndrea Driscoll, Henry Krum, Rory Wolfe, et al.
International Journal of Cardiology|May 8, 2018
The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspectiveRadya Kumar, Andrew Tonkin, Danny Liew, et al.
Current Opinion in Cardiology|May 29, 2014
Statins in the elderly: an answered question?Sophia Zoungas, Andrea Curtis, Andrew Tonkin, et al.
The Cochrane Database of Systematic Reviews|December 23, 2015
Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fractionAndrea Driscoll, Judy Currey, Andrew Tonkin, et al.
Heart, Lung & Circulation|December 15, 2005
What becomes of the broken hearted? Coronary heart disease as a paradigm of cardiovascular disease and poor health among indigenous australiansAlex Brown, Warren Walsh, Traven Lea, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|June 22, 2010
Best practice for prevention and treatment of cardiovascular disease through an equity lens: a reviewAlison Beauchamp, Anna Peeters, Andrew Tonkin, et al.
International Journal of Cardiology|September 18, 2018
Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspectiveZanfina Ademi, Ella Zomer, Andrew Tonkin, et al.
Clinical Pharmacology and Therapeutics|July 14, 2018
LDL-Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) RiskRichard Ofori-Asenso, Sophia Zoungas, Andrew Tonkin, et al.
Seminars in Thrombosis and Hemostasis|March 17, 2012
High platelet reactivity and antiplatelet therapy resistanceMatthew D Linden, Huyen Tran, Robyn Woods, et al.
Pageof 17